Inadequate antimicrobial therapy is a critical determinant of survival in patients admitted to ICU, with overwhelming infection requiring renal replacement therapy (RRT). Guidelines for effective dosing are not available because RRT can be significantly different between ICUs, resulting in antimicrobial pharmacokinetics that could be inadequate in up to 40% of antimicrobial doses. Developing an evidenced based antimicrobial dosing guideline is of global significance and should be considered a priority to improving clinical outcomes for patients with significant infections requiring RRT.

The aim of the SMARRT Study is to develop optimised antimicrobial dosing guidelines for ICU patients with life-threatening infections that account for patient characteristics and the type of RRT they are prescribed. This study will focus on piperacillin/tazobactam, meropenem, vancomycin and linezolid.

Project members

Professor Jason Roberts

Chief Investigator and CRE lead

Professor Jeffrey Lipman

Chief Investigator

Professor John Turnidge

Chief Investigator

Professor Gavin Joynt

Chief Investigator

Professor Sanjoy Paul

Chief Investigator

Professor Rinaldo Bellomo

Associate Investigator

Professor Jean-Yves Lefrant

Associate Investigator

Dr Despoina Koulenti

Associate Investigator

Dr Cornelia Landersdorfer

Associate Investigator